Exon skipping antisense oligonucleotides (AONs) have been extensively studied as a promising method of treating Duchenne muscular dystrophy (DMD), yet the clinical efficacy of the conditionally approved AONs still remains low. Using phosphorothioated locked nucleic acid/2′-fluoro-RNA AONs, we aimed to increase AON efficiency by employing skeletal muscle-targeting conjugate molecules, cholesterol, and docosanoic acid to improve the biodistribution of the therapeutic. While conjugate molecules were able to induce high levels of skipping in an in vitro model, in vivo studies in the hDMDdel52/mdx mouse model caused adverse symptomatic and systemic immune reactions, up to and including death, with little to no appreciable increase in exon skipping. Our study cautions against using these AON conjugates in an animal model due to severe toxicity.
Aartsma-RusA, Bremmer-BoutM, JansonAAM, et al.Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord, 2002; 12(Suppl 1):S71–S77; doi: 10.1016/s0960-8966(02)00086-x
2.
Aartsma-RusA. Overview on AON design. Methods Mol Biol, 2012; 867:117–129; doi: 10.1007/978-1-61779-767-5_8
3.
HoffmanEP, FischbeckKH, BrownRH, et al.Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med, 1988; 318:1363–1368; doi: 10.1056/NEJM198805263182104
4.
Aartsma-RusA. The future of exon skipping for Duchenne muscular dystrophy. Hum Gene Ther, 2023; 34:372–378; doi: 10.1089/hum.2023.026
5.
Aartsma-RusA, FokkemaI, VerschuurenJ, et al.Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat, 2009; 30:293–299; doi: 10.1002/humu.20918
6.
ZhangY, WuZ. Gene therapy for monogenic disorders: Challenges, strategies, and perspectives. J Genet Genomics, 2024; 51:133–143; doi: 10.1016/j.jgg.2023.08.001
ChabowskiA, GórskiJ. Muscle lipid metabolism. In: Muscle and Exercise Physiology. (ZoladzJA. ed.) Academic Press, an imprint of Elsevier Inc: Cambridge; 2019; pp. 271–284.
9.
BiscansA, CaiazziJ, McHughN, et al.Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol Ther, 2021; 29:1382–1394; doi: 10.1016/j.ymthe.2020.12.023
10.
BiscansA, ColesA, HarasztiRA, et al.Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res, 2019; 47:1082–1096; doi: 10.1093/nar/gky1239
11.
GurusingheA, de NieseM, RenaudJ, et al.The binding of lipoproteins to human muscle cells: Binding and uptake of LDL, HDL, and alpha-tocopherol. Muscle Nerve, 1988; 11:1231–1239; doi: 10.1002/mus.880111207
12.
EngelbeenS, O’ReillyD, Van De VijverD, et al.Challenges of assessing exon 53 skipping of the human DMD transcript with locked nucleid acid-modified antisense oligonucleotides in a mouse model for Duchenne muscular dystrophy. Nucleic Acid Ther, 2023; 33:348–360; doi: 10.1089/nat.2023.0038
13.
Aartsma-RusA, KamanWE, WeijR, et al.Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther, 2006; 14:401–407; doi: 10.1016/j.ymthe.2006.02.022
14.
VeltropM, van VlietL, HulskerM, et al.A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS One, 2018; 13:e0193289–e0193289; doi: 10.1371/journal.pone.0193289
15.
SoulierJP, BursteinM. Hemorrhagic diathesis associated with the presence of an anticoagulant in circulating blood: Case report and laboratory studies. Blood, 1948; 3:1188–1196.
16.
KhanT, WeberH, DiMuzioJ, et al.Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol Ther Nucleic Acids, 2016; 5:e342; doi: 10.1038/mtna.2016.55
17.
OsbonMF, ColesAH, BiscansA, et al.Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids Res, 2019; 47:1070–1081; doi: 10.1093/nar/gky1232
18.
HaradaK, FurukawaH, KoharaH, et al.The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotides. Toxicol In Vitro, 2023; 89:105569; doi: 10.1016/j.tiv.2023.105569
19.
BiscansA, LyS, McHughN, et al.Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo. J Control Release, 2022; 349:831–843; doi: 10.1016/j.jconrel.2022.07.041
20.
GaleaI. The blood-brain barrier in systemic infaction and inflammation. Cell Mol Immunol, 2021; 18:2489–2501; doi: 10.1038/s41423-021-00757-x
21.
YoshiokaY, YamamotoS, KusamoriK, et al.Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide. J Control Release, 2025; 380:787–799; doi: 10.1016/j.jconrel.2025.02.025
22.
GearyRS, NorrisD, YuR, et al.Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 2015; 87:46–51; doi: 10.1016/j.addr.2015.01.008
HarveyJW. Evaluation of leukocytic disorders. In: Veterinary Hematology (HarveyJW. ed.) Saunders, an imprint of Elsevier Inc: St. Louis; 2012; pp. 122–176.
25.
HenrySP, SeguinR, CavagnaroJ, et al.Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics. Nucleic Acid Ther, 2016; 26:210–215; doi: 10.1089/nat.2015.0593
26.
ChenS, LeBT, ChakravarthyM, et al.Systematic evaluation of 2′-fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro. Sci Rep, 2019; 9:6078; doi: 10.1038/s41598-019-42523-0
27.
GauerRL, WhitakerDJ. Thrombocytopenia: Evaluation and management. Am Fam Physician, 2022; 106:288–298.
28.
NorresethadaL, KhumpooW, RattarittamrongE, et al.The use of mean platelet volume for distinguishing the causes of thrombocytopenia in adult patients. Hematol Rep, 2019; 11:7732; doi: 10.4081/hr.2019.7732
TuranovAA, LoA, HasslerMR, et al.RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol, 2018; 36:1164–1173; doi: 10.1038/nbt.4297
31.
SunF, de NieuwburghMP, HubinontC, et al.Gene therapy in preeclampsia: The dawn of a new era. Hypertens Pregnancy, 2024; 43:2358761; doi: 10.1080/10641955.2024.2358761
32.
HaradaK, WenlongW, ShinozawaT. Physiological platelet aggregation assay to mitigate drug-induced thrombocytopenia using a microphysiological system. Sci Rep, 2024; 14:14109; doi: 10.1038/s41598-024-64063-y
33.
PrakashTP, MullickAE, LeeRG, et al.Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res, 2019; 47:6029–6044; doi: 10.1093/nar/gkz354
34.
ØstergaardME, JacksonM, LowA, et al.Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res, 2019; 47:6045–6058; doi: 10.1093/nar/gkz360
35.
ChappellAE, GausHJ, BerdejaA, et al.Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice. Nucleic Acids Res, 2020; 48:4382–4395; doi: 10.1093/nar/gkaa164
36.
ChanDPY, DeleaveyGF, OwenSC, et al.Click conjuga ted polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. Biomaterials, 2013; 34:8408–8415; doi: 10.1016/j.biomaterials.2013.07.019
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
